{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:39:45Z","timestamp":1785451185730,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004702","name":"Baxter International","doi-asserted-by":"publisher","award":["M000000346978"],"award-info":[{"award-number":["M000000346978"]}],"id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03365-1","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T07:14:52Z","timestamp":1748070892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the impact of continuous venovenous hemodiafiltration on the efficacy of prophylactic fondaparinux doses: a prospective single-center observational study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6073-0588","authenticated-orcid":false,"given":"Aleksander","family":"Aszkie\u0142owicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5353-9849","authenticated-orcid":false,"given":"Karol P.","family":"Steckiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3441-5162","authenticated-orcid":false,"given":"Rados\u0142aw","family":"Owczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"issue":"1","key":"3365_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s13054-015-1003-9","volume":"19","author":"C Minet","year":"2015","unstructured":"Minet, C. et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit. Care. 19 (1), 287 (2015).","journal-title":"Crit. Care"},{"issue":"4","key":"3365_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ccc.2011.07.001","volume":"27","author":"AG McLeod","year":"2011","unstructured":"McLeod, A. G. & Geerts, W. Venous thromboembolism prophylaxis in critically ill patients. Crit. Care Clin. 27 (4), 765\u2013780 (2011).","journal-title":"Crit. Care Clin."},{"key":"3365_CR3","doi-asserted-by":"crossref","unstructured":"Neuenfeldt, F. S., Weigand, M. A. & Fischer, D. Coagulopathies in intensive care medicine: balancing act between thrombosis and bleeding. J. Clin. Med.  10 (22). (2021).","DOI":"10.3390\/jcm10225369"},{"key":"3365_CR4","doi-asserted-by":"crossref","unstructured":"Levi, M. & Opal, S. M. Coagulation abnormalities in critically Ill patients.  Surg.  Intensive Care Med. (2016).","DOI":"10.1007\/978-3-319-19668-8_34"},{"issue":"4","key":"3365_CR5","first-page":"559","volume":"13","author":"A Malato","year":"2015","unstructured":"Malato, A. et al. The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfus. 13 (4), 559\u2013568 (2015).","journal-title":"Blood Transfus."},{"issue":"1","key":"3365_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00134-022-06850-7","volume":"49","author":"J Helms","year":"2023","unstructured":"Helms, J., Middeldorp, S. & Spyropoulos, A. C. Thromboprophylaxis in critical care. Intensive Care Med. 49 (1), 75\u201378 (2023).","journal-title":"Intensive Care Med."},{"issue":"1","key":"3365_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40360-023-00643-4","volume":"24","author":"D Ghaziri","year":"2023","unstructured":"Ghaziri, D. et al. Novel Fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol. BMC Pharmacol. Toxicol. 24 (1), 2 (2023).","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"1","key":"3365_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12882-017-0487-8","volume":"18","author":"J Koeze","year":"2017","unstructured":"Koeze, J. et al. Incidence, timing and outcome of AKI in critically ill patients varies with the definition used and the addition of urine output criteria. BMC Nephrol. 18 (1), 70 (2017).","journal-title":"BMC Nephrol."},{"issue":"10","key":"3365_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3109\/0886022X.2012.723515","volume":"34","author":"MS Paudel","year":"2012","unstructured":"Paudel, M. S. et al. A study of incidence of AKI in critically ill patients. Ren. Fail. 34 (10), 1217\u20131222 (2012).","journal-title":"Ren. Fail."},{"issue":"4","key":"3365_CR10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1097\/01.ASN.0000059863.48590.E9","volume":"14","author":"EA Hoste","year":"2003","unstructured":"Hoste, E. A. et al. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J. Am. Soc. Nephrol. 14 (4), 1022\u20131030 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"3365_CR11","first-page":"691013","volume":"2012","author":"R Cartin-Ceba","year":"2012","unstructured":"Cartin-Ceba, R. et al. Risk factors for development of acute kidney injury in critically ill patients: a systematic review and meta-analysis of observational studies. Crit. Care Res. Pract. 2012 (1), 691013 (2012).","journal-title":"Crit. Care Res. Pract."},{"issue":"8","key":"3365_CR12","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s001340050670","volume":"24","author":"G Vivino","year":"1998","unstructured":"Vivino, G. et al. Risk factors for acute renal failure in trauma patients. Intensive Care Med. 24 (8), 808\u2013814 (1998).","journal-title":"Intensive Care Med."},{"issue":"5","key":"3365_CR13","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.ki.5002743","volume":"73","author":"Z Ricci","year":"2008","unstructured":"Ricci, Z., Cruz, D. & Ronco, C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int. 73 (5), 538\u2013546 (2008).","journal-title":"Kidney Int."},{"issue":"1","key":"3365_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2110-5820-1-32","volume":"1","author":"PM Honore","year":"2011","unstructured":"Honore, P. M. et al. Septic AKI in ICU patients. Diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments. Ann. Intensive Care. 1 (1), 32 (2011).","journal-title":"Ann. Intensive Care"},{"issue":"1","key":"3365_CR15","doi-asserted-by":"publisher","first-page":"106e7","DOI":"10.1016\/j.jcrc.2011.05.013","volume":"27","author":"SS Badawy","year":"2012","unstructured":"Badawy, S. S. & Fahmy, A. Efficacy and cardiovascular tolerability of continuous veno-venous hemodiafiltration in acute decompensated heart failure: a randomized comparative study. J. Crit. Care. 27 (1), 106e7\u201310613 (2012).","journal-title":"J. Crit. Care"},{"issue":"1","key":"3365_CR16","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1038\/s41598-019-42783-w","volume":"9","author":"M Voigt","year":"2019","unstructured":"Voigt, M. et al. Retention of beneficial molecules and coagulation factors during haemodialysis and haemodiafiltration. Sci. Rep. 9 (1), 6370 (2019).","journal-title":"Sci. Rep."},{"key":"3365_CR17","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhang, M., Tan, L., Pan, N. & Zhang, L. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide - PubMed. Progr.  Mol.  Biol.   Transl. Sci. 163  (2019).","DOI":"10.1016\/bs.pmbts.2019.02.004"},{"issue":"18","key":"3365_CR18","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa011100","volume":"345","author":"BI Eriksson","year":"2001","unstructured":"Eriksson, B. I., Bauer, K. A., Lassen, M. R. & Turpie, A. G. Steering committee of the pentasaccharide in Hip-Fracture surgery S. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl. J. Med. 345 (18), 1298\u20131304 (2001).","journal-title":"N Engl. J. Med."},{"issue":"18","key":"3365_CR19","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa011099","volume":"345","author":"KA Bauer","year":"2001","unstructured":"Bauer, K. A., Eriksson, B. I., Lassen, M. R. & Turpie, A. G. Steering committee of the pentasaccharide in major knee surgery S. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl. J. Med. 345 (18), 1305\u20131310 (2001).","journal-title":"N Engl. J. Med."},{"issue":"9319","key":"3365_CR20","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","volume":"359","author":"MR Lassen","year":"2002","unstructured":"Lassen, M. R., Bauer, K. A., Eriksson, B. I., Turpie, A. G. & European Pentasaccharide Elective Surgery Study Steering C. Postoperative Fondaparinux versus preoperative Enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359 (9319), 1715\u20131720 (2002).","journal-title":"Lancet"},{"issue":"6","key":"3365_CR21","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens, S. M. et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160 (6), 2247\u20132259 (2021).","journal-title":"Chest"},{"key":"3365_CR22","unstructured":"Kakkos, S. K. et al. (eds) \u2018s Choice \u2013 European society for vascular surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur.  J. Vasc. Endovasc. Surg. 61 (1), 9\u201382. (2021)."},{"key":"3365_CR23","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2147\/DDDT.S38042","volume":"7","author":"M Di Nisio","year":"2013","unstructured":"Di Nisio, M. & Porreca, E. Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) Fondaparinux. Drug Des. Devel Ther. 7, 973\u2013980 (2013).","journal-title":"Drug Des. Devel Ther."},{"issue":"11","key":"3365_CR24","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1111\/j.1538-7836.2012.04908.x","volume":"10","author":"W Ageno","year":"2012","unstructured":"Ageno, W. et al. Safety and efficacy of low-dose Fondaparinux (1.5\u00a0mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study. J. Thromb. Haemost. 10 (11), 2291\u20132297 (2012).","journal-title":"J. Thromb. Haemost."},{"key":"3365_CR25","doi-asserted-by":"crossref","unstructured":"Silvestri, F. et al. Safety and efficacy of thromboprophylaxis with fondaparinux in elderly acutely ill medical patients with renal impairment: a retrospective single center study. Italian J.  Med. 7 (4). (2013).","DOI":"10.4081\/itjm.2013.287"},{"issue":"9309","key":"3365_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(02)07920-5","volume":"359","author":"J D\u00f6rffler-Melly","year":"2002","unstructured":"D\u00f6rffler-Melly, J. et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 359 (9309), 849\u2013850 (2002).","journal-title":"Lancet"},{"issue":"Suppl 2(Supplem","key":"3365_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","volume":"41","author":"F Donat","year":"2002","unstructured":"Donat, F. et al. The pharmacokinetics of Fondaparinux sodium in healthy volunteers. Clin. Pharmacokinet. 41 (Suppl 2(Supplement 2), 1\u20139 (2002).","journal-title":"Clin. Pharmacokinet."},{"key":"3365_CR28","doi-asserted-by":"crossref","unstructured":"Perez, R. et al. Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients. Crit. Care 26 (1). (2022).","DOI":"10.1186\/s13054-022-04163-1"},{"issue":"4","key":"3365_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jcrc.2010.08.004","volume":"26","author":"G Cumbo-Nacheli","year":"2011","unstructured":"Cumbo-Nacheli, G., Samavati, L. & Guzman, J. A. Bioavailability of Fondaparinux to critically ill patients. J. Crit. Care. 26 (4), 342\u2013346 (2011).","journal-title":"J. Crit. Care"},{"issue":"1","key":"3365_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00228-021-03201-1","volume":"78","author":"D Michali\u010dkov\u00e1","year":"2021","unstructured":"Michali\u010dkov\u00e1, D. et al. Population pharmacokinetics-pharmacodynamics of Fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Eur. J. Clin. Pharmacol. 78 (1), 89\u201398 (2021).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"3365_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/8755122514567316","volume":"31","author":"MH Al-Shaer","year":"2015","unstructured":"Al-Shaer, M. H. & Ibrahim, T. Safety and efficacy of Fondaparinux in renal impairment. J. Pharm. Technol. 31 (4), 161\u2013166 (2015).","journal-title":"J. Pharm. Technol."},{"issue":"Suppl 2(Supplem","key":"3365_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/00003088-200241002-00002","volume":"41","author":"F Paolucci","year":"2002","unstructured":"Paolucci, F., Clavies, M. C., Donat, F. & Necciari, J. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin. Pharmacokinet. 41 (Suppl 2(Supplement 2), 11\u201318 (2002).","journal-title":"Clin. Pharmacokinet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03365-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03365-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03365-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T07:14:55Z","timestamp":1748070895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03365-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3365"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03365-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study protocol was approved on 3 July 2020 and 21 May 2021 by the Independent Bioethics Committee for Scientific Research at the Medical University of Gda\u0144sk (approval no. NKBBN\/382\/2020 and NKBBN\/382\u2013496\/2021). The study was performed in accordance with the ethical standards provided in the 1964 Declaration of Helsinki and its later amendments. All participants gave informed written consent before enrollment in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}}],"article-number":"18083"}}